BERGENBIO’S BEMCENTINIB SELECTED TO BE FAST-TRACKED AS POTENTIAL TREATMENT FOR COVID-19 THROUGH NEW NATIONAL UK GOVERNMENT CLINICAL TRIAL INITIATIVE
· Bemcentinib selected as first candidate to be tested through new ACCORD study · The Phase II clinical trial initiative to rapidly investigate bemcentinib’s efficacy and safety in hospitalised COVID-19 patients · Study to be funded by the UK Department of Health and Social Care and UK Research and Innovation · Study to be managed by CRO, IQVIA · BerGenBio will be hosting a webcast at 10.00 CEST tomorrow (see details below) Bergen, Norway, 28 April 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors